Spinal cord injury (SCI) remains a major cause of lifelong neurological disability, with limited therapeutic options capable of restoring function once axonal pathways, myelin integrity, and segmental spinal circuitry are disrupted.

Cell-based regenerative approaches have therefore attracted substantial attention, particularly transplantation of neural stem cells (NSCs) and neural progenitor cells (NPCs), which can survive within injured spinal cord tissue, differentiate into neuronal and glial lineages, and extend axons capable of forming synaptic connections with host circuits. Despite this promise, clinical translation of neural graft–based strategies has been constrained by the complex biology of secondary injury, including ischemia, excitotoxic signaling, inflammatory amplification, and metabolic dysfunction, as well as by challenges related to graft survival, circuit integration, and incomplete reconnection of long descending tracts. Among the molecular processes shaping these constraints, mitochondrial dysfunction has emerged as a principal component of secondary injury biology. Disruption of mitochondrial bioenergetics contributes to oxidative stress, apoptotic signaling, and axonal degeneration, while also influencing neural progenitor survival, differentiation, and regenerative capacity. In experimental models of SCI, mitochondria-targeted peptides stabilize mitochondrial function, reduce oxidative injury, and improve neurological recovery, highlighting mitochondrial stabilization as a tractable therapeutic axis. In parallel, advances in extracellular vesicle biology have revealed that placenta-derived extracellular vesicles (pEVs) and related placenta–brain signaling pathways represent a scalable source of developmentally patterned immunomodulatory and trophic signals capable of influencing neural repair processes.

These vesicular systems carry regulatory RNA, proteins, and lipid mediators that can modulate inflammation, vascular stability, and progenitor cell behavior, suggesting a potential role in reprogramming the injury microenvironment.

Recent trials of allogeneic mesenchymal stromal cell products have demonstrated sustained improvements in functional outcomes in age-related frailty, illustrating the capacity of cell-based or cell-derived therapeutics to exert systemic regenerative signals in humans. Within this framework, a high-potency therapeutic architecture for SCI may combine developmentally patterned spinal or brain– specified NPCs with mitochondria-targeted peptides and nanoformulated organopeptidic biologics derived from spinal cord, central nervous system, or placental signaling systems. Such a strategy aims to simultaneously reconstruct disrupted neural circuits, stabilize mitochondrial bioenergetics during secondary injury, and remodel immune and vascular niches that influence regenerative integration. The present review outlines the mechanistic rationale for this integrated platform and discusses translational considerations intended to maximize therapeutic potency while preserving safety and clinical feasibility.